Autonomix Medical (AMIX) said Friday that it finalized the design of its Application Specific Integrated Circuits, or ASIC, microchip for its sensing technology catheter, following successful in vivo preclinical and bench testing.
This marks a key step toward the pivotal clinical trial of the device in the US, planned for 2025, according to the company.
The ASIC microchip is designed to facilitate nerve signal detection through vascular pathways, the company added.
Achieving this technical milestone should pave the way for commercialization of the company's Autonomix Sensing and RF Ablation System in the US as a treatment for pancreatic cancer pain, it said.
Shares of Autonomix Medical were up 8.5% in recent trading.
Price: 3.10, Change: +0.24, Percent Change: +8.53
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。